Moolec Science Sa's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Moolec Science Sa (MLEC) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Moolec Science Sa vs Its Competitors
- TTM: Trailing 12-month revenue of 297M vs 1,365M combined for tracked competitors (17.9% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months), vs holding steady (-1.8%) for its tracked peer group.
- Growth: Moolec Science Sa generated 11,125.5% revenue growth year over year in Q4 2025, vs 6.3% for its tracked competitors combined.
- Profitability: Its -59.5% net margin compares with 35.4% for the peer group.
- Scale: Moolec Science Sa ranks #46 of 51 companies by market capitalization in the Apparel, Footwear & Accessories industry, holding 0.0% of industry market cap.
- Peer revenue share: Moolec Science Sa accounted for 47.0% of combined revenue among its tracked peer group, up from 0.8% a year earlier.
- Peer differentiation: Revenue per employee of $2.88M compares with $0.30M for the peer group (9.7x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
MLEC Sales vs. its Competitors, Q4 2025
Moolec Science Sa reported revenue growth of 11,125.54 % year on year in Q4 2025, above its competitors' combined revenue growth of 6.28 %.
With a net margin of -59.54 %, Moolec Science Sa reported lower profitability than its competitors (35.44 %).
Moolec Science Sa generated 46.97 % of the combined sales of its peer group, up from 0.83 % a year earlier.
Moolec Science Sa vs. its Competitors, Q4 2025
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Moolec Science Sa reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Moolec Science Sa and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Moolec Science Sa | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (5) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Moolec Science Sa's competitor groups requires a Commercial License.
For context: the Apparel, Footwear & Accessories industry grew revenue 8.6% year over year, combined, vs 11,125.5% for Moolec Science Sa. Moolec Science Sa's share of combined industry revenue moved from 0.00% to 0.40%, a gain of 0.39 percentage points.
Moolec Science Sa's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Moolec Science Sa | No | Yes | Yes | Yes |
| Competitors combined (2) | ||||
| Similar-Size Competitors (4) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
MLEC Stock Performance relative to its Competitors
MLEC Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | First Bancorp | 282.9% | Outperformed |
| 2 | First Bancorp | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Moolec Science Sa's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Moolec Science Sa's Comment on Competition and Industry Peers
Publicly Traded Peers of Moolec Science Sa
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Moolec Science Sa |
- | 296.69 |
 First Bancorp |
4,170.08 | 954.21 |
 First Bancorp |
2,665.40 | 410.68 |
| SUBTOTAL | 6,835.48 | 1,661.58 |
Sources: Moolec Science Sa's official press releases and company reports; CSIMarket.com's market research; and the company reports and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Moolec Science Sa versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Moolec Science Sa's Competitors Named by the Company
Competitive relationships identified from Moolec Science Sa reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| First Bancorp | Company report | 85% |
| First Bancorp | Company report | 85% |
Company report basis, confidence, active dates and source counts for Moolec Science Sa's named competitors require a Commercial License.
Methodology: relationships are extracted from Moolec Science Sa reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.
Moolec Science Sa's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Moolec Science Sa | - | 2,880,457 | -1,714,948 |
| First Bancorp | 4,170 | 296,523 | 115,773 |
| First Bancorp | 2,665 | 298,892 | 96,823 |
| PEERS TOTAL | 6,835 | 297,232 | 110,103 |
Moolec Science Sa's Position in Industry Market Structure
Market-capitalization share and concentration across all 46 companies in Moolec Science Sa's industry classification, broader than the peer set above. Market cap in millions of $.Moolec Science Sa ranks #46 of 46 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,354, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Cintas Corporation | 86,664 | 28.37 % |
| 2 | Nike Inc | 55,723 | 18.24 % |
| 3 | Ralph Lauren Corporation | 23,875 | 7.81 % |
| 4 | Tapestry Inc | 22,981 | 7.52 % |
| 5 | Amer Sports Inc | 1,234 | 5.2% |
| 6 | Lululemon Athletica Inc | 1,234 | 5.2% |
| 7 | Deckers Outdoor Corp | 1,234 | 5.2% |
| 8 | On Holding Ag | 1,234 | 5.2% |
| 9 | Levi Strauss and Co | 1,234 | 5.2% |
| 10 | V F Corporation | 1,234 | 5.2% |
| 46 | Moolec Science Sa | 0 | 0.00 % |
Market cap and industry share for the rest of Moolec Science Sa's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-10-27.
Moolec Science Sa's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 41 | Allbirds Inc | 20 | -67.92 % |
| 42 | Tandy Leather Factory Inc | 19 | - |
| 43 | Perfect Moment Ltd | 1,234 | 12.3% |
| 44 | Ping An Biomedical Co Ltd | 1,234 | 12.3% |
| 45 | Neo Concept International Group Holdings Limited | 1,234 | 12.3% |
| 46 | Moolec Science Sa | 0 | -84.71 % |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Moolec Science Sa's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-10-27. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Moolec Science Sa's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Apparel, Footwear & Accessories industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (69 companies). See the full Apparel, Footwear & Accessories industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 31.43 % | 35.25 % (avg) | -3.8 pp |
| Operating Margin | -35.10 % | industry median | -40.5 pp |
| EBITDA Margin | -55.27 % | -0.10 % (avg) | -55.2 pp |
| Capital Intensity (Capex / Revenue) | 1.90 % | 3.00 % (avg) | -1.1 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Moolec Science Sa's BCG Growth-Share Matrix
Relative market share (vs Moolec Science Sa's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Moolec Science Sa falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 5.8% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Moolec Science Sa's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,354 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 1.90 % vs industry average 3.00 % (see Profitability & Cost Structure above) |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments. Supplier power and buyer power are not assessed here -- see Moolec Science Sa's dedicated Suppliers and Customers pages for concentration data; threat of substitutes has no systematic data source in this system and is not estimated.
Moolec Science Sa's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Moolec Science Sa falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Moolec Science Sa's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
Weaknesses
- Operating margin 40.5 points below the industry median.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Moolec Science Sa's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Moolec Science Sa | 0.00 | 0.13 | - |
| First Bancorp | 0.05 | 0.53 | 0.14 |
| First Bancorp | 0.01 | 0.05 | 0.05 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Moolec Science Sa's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Moolec Science Sa | Q2 2025 | +5,174.3 % | - |
| First Bancorp | Q2 2026 | +9.4 % | +19.9 % |
| First Bancorp | Q2 2026 | +15.9 % | +30.4 % |
| PEERS TOTAL | +96.8 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Moolec Science Sa's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Moolec Science Sa | Q2 2025 | +3,848.0 % | +3,470.5 % |
| First Bancorp | Q2 2026 | +1,584.5 % | +93.1 % |
| First Bancorp | Q2 2026 | -47.2 % | -26.1 % |
Moolec Science Sa's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Moolec Science Sa | - | - | - |
| First Bancorp | 1.94% | 5.76% | 19.03% |
| First Bancorp | 1.04% | 2.84% | 7.99% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Moolec Science Sa's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Moolec Science Sa | - | - |
| First Bancorp | 11.46 | 4.37 |
| First Bancorp | 20.02 | 6.49 |
| PEERS AVERAGE | 20.78 | 4.11 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.